Immunotherapy Drugs Show Major Progress in Early-Stage Cancer

Drugs that boost the body’s immune system to fight disease are showing promise in treating a variety of cancers in earlier stages, a development primed to expand their use and transform care for stubborn diseases like gastric and colon cancer.

Immunotherapy treatments such as Opdivo from Bristol Myers Squibb Co., Imfinzi from AstraZeneca PLC, and Roche Holding AG’s Tecentriq have become bestsellers by increasing survival times in a number of advanced cancers.